Deals
A mostly black box since emerging with more than a billion dollars in hand, Xaira Therapeutics is slowly pulling back the curtain, revealing plans to find partners and validate its pipeline.
FEATURED STORIES
The total of 52 mergers and acquisitions for the first half of 2026 reflects what analysts, industry watchers and executives are saying over and over: M&A is back.
Dealmaking across biopharma is shifting dramatically as the SEC rolls out new regulations to ease burdens on newly public companies and antitrust review is replaced by drug pricing as the policy concern du jour.
Dual and even triple or quadruple track processes have come roaring back in 2026 thanks to a glut of M&A that has refilled investors’ wallets. Big Pharma is being put on notice that time is critical if they want to acquire.
Subscribe to BioPharm Executive
Market insights and trending stories for biopharma leaders, in your inbox every Wednesday
THE LATEST
T cell redirecting cancer company Immatics Biotechnologies entered into a merger agreement with Arya Sciences Acquisition Corp. that will give the Germany-based company a listing on the Nasdaq exchange under the ticker symbol IMTX.
The consent decree, including the proposed purchasers, remains subject to further review and approval by the Commissioners of the FTC.
AcelRx Pharmaceuticals, headquartered in Redwood City, California, is buying Watertown, Massachusetts-based TetraPhase Pharmaceuticals for $14.4 million.
Consumer healthcare company HRA Pharma grew their total group revenues by 20.8% in 2019 with EBITDA growing by 30%
The new company is focused on tapping into the powers of the immune system to address numerous diseases.
Numab Therapeutics announced the closing of its Series B financing round at a total volume of CHF 22M. New investors in this round included 3SBio/Sunshine Guojian, Mitsubishi UFJ Capital Co., Ltd. and Eisai Co., Ltd. as well as Numab’s board member Dr. Daniel Vasella.
Mergers and acquisitions in the pharmaceutical industry are not only a positive for the company that has made a bid for another company, but it is also good for the industry as a whole because of increases in efficiency across the entire field.
Deerfield Management placed Melinta’s assets up for auction, but no other companies made competing bids, leaving Deerfield in control of the company’s assets.
On Tuesday, the European Commission gave the green light to the merger following the divestiture of an investigational autoimmune treatment.
Polarean Imaging plc announces that it has issued 232,010 new ordinary shares of £0.00037 each in the capital of the Company at par value, following the exercise of warrants by Amphion Innovations plc.